Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees

With tyrosine kinase inhibitor (TKI) therapy, chronic myelogenous leukemia (CML) is now a chronic disease. CML patients treated with TKIs (n=1,200) were identified from the OptumLabs(®) Data Warehouse (de-identified claims and electronic health records) between 2000-2016 and compared with a non-canc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leuk Lymphoma
Egile Nagusiak: Chow, Eric J., Doody, David R., Wilkes, Jennifer J., Becker, Laura K., Chennupati, Shasank, Morin, Pamela E., Winestone, Lena E., Henk, Henry J., Lyman, Gary H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8106632/
https://ncbi.nlm.nih.gov/pubmed/33283555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1855340
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak